The cost effectiveness of licensed oromucosal midazolam (Buccolam(®)) for the treatment of children experiencing acute epileptic seizures: an approach when trial evidence is limited.
about
A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe.Nonintravenous rescue medications for pediatric status epilepticus: A cost-effectiveness analysis.A systematic review of economic evaluations of treatments for patients with epilepsy.A Systematic Review and Meta-Analysis of Childhood Health Utilities.Carers' express positive views on the acceptability, efficacy and safety of buccal midazolam for paediatric status epilepticus.Midazolam vs diazepam in prolonged seizures in children: A pharmacoeconomic approach.
P2860
The cost effectiveness of licensed oromucosal midazolam (Buccolam(®)) for the treatment of children experiencing acute epileptic seizures: an approach when trial evidence is limited.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
The cost effectiveness of lice ...... hen trial evidence is limited.
@en
The cost effectiveness of licensed oromucosal midazolam
@nl
type
label
The cost effectiveness of lice ...... hen trial evidence is limited.
@en
The cost effectiveness of licensed oromucosal midazolam
@nl
prefLabel
The cost effectiveness of lice ...... hen trial evidence is limited.
@en
The cost effectiveness of licensed oromucosal midazolam
@nl
P2093
P2860
P1433
P1476
The cost effectiveness of lice ...... hen trial evidence is limited.
@en
P2093
Anthony J Batty
Daniel Gladwell
Elaine Tate
Nic Brereton
P2860
P2888
P304
P356
10.1007/S40272-013-0009-5
P577
2013-04-01T00:00:00Z
P6179
1036381322